Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Descriptive Preanalytical Survey of Procedures Followed for the Screening of Glucose Dysregulation in Thalassemia Centers: Implications for Clinical Practice and Call for Harmonization.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Congenital Amegakaryocytic Thrombocytopenia Presenting With Features of Immune Thrombocytopenia: A Case Report.

Cureus·2026
Same author

Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with New Diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM): Implications for Clinical Practice.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Fasting Plasma Glucose Levels within the High Normal Range are Associated with a Significantly Increased Risk of Future Dysglycemia in Transfusion-Dependent β Thalassemia: A Decade-Long Multicenter Retrospective Analysis.

Mediterranean journal of hematology and infectious diseases·2025
Same author

Gynecologic and obstetric complications in women with congenital fibrinogen disorders: insights from the Prospective Rare Bleeding Disorders Database.

Research and practice in thrombosis and haemostasis·2025
Same author

Acute graft-vs-host disease, pathophysiology, prevention, and treatment: Something old and something new.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2025
Same journal

Aortic Area as an Indicator of Subclinical Cardiovascular Disease.

The open cardiovascular medicine journal·2026
Same journal

Diminished Returns of Educational Attainment on Heart Disease among Black Americans.

The open cardiovascular medicine journal·2020
Same journal

Hyperbaric Oxygen Therapy in Ischaemic Foot Ulcers in Type 2 Diabetes: A Clinical Trial.

The open cardiovascular medicine journal·2018
Same journal

Trends of Cardiovascular Disease Mortality in Relation to Population Aging in Greece (1956 - 2015).

The open cardiovascular medicine journal·2018
Same journal

Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.

The open cardiovascular medicine journal·2018
Same journal

False Positive Troponin I Rendering Two Admissions for "Recurrent Acute Myopericarditis".

The open cardiovascular medicine journal·2018
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Cancer-associated thrombosis.

Mehran Karimi1, Nader Cohan

  • 1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

The Open Cardiovascular Medicine Journal
|April 3, 2010
PubMed
Summary
This summary is machine-generated.

Cancer patients face high risks of venous thromboembolism (VTE), a serious complication. Low-molecular-weight heparin (LMWH) is recommended for VTE prophylaxis and treatment, improving survival and quality of life.

Keywords:
CancerLow-molecular-weight heparin.Thrombosis

More Related Videos

Three-dimensional Co-culture Model for Tumor-stromal Interaction
08:39

Three-dimensional Co-culture Model for Tumor-stromal Interaction

Published on: February 2, 2015

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Related Experiment Videos

Last Updated: Jun 14, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Three-dimensional Co-culture Model for Tumor-stromal Interaction
08:39

Three-dimensional Co-culture Model for Tumor-stromal Interaction

Published on: February 2, 2015

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Area of Science:

  • Oncology
  • Hematology
  • Vascular Medicine

Background:

  • Thrombosis is a frequent and serious complication in cancer patients, affecting approximately 20% and contributing to significant morbidity and mortality.
  • Cancer-associated thrombosis shares risk profiles with inflammation-induced atherosclerosis, with factors like cancer type, chemotherapy, and surgery increasing VTE risk.

Purpose of the Study:

  • To review the current understanding and management of cancer-associated thrombosis.
  • To highlight the efficacy and safety of low-molecular-weight heparin (LMWH) in VTE prophylaxis and treatment for cancer patients.

Main Methods:

  • Review of landmark studies and current guidelines on cancer-associated venous thromboembolism (VTE).
  • Evaluation of risk factors, prophylaxis strategies, and therapeutic options, focusing on low-molecular-weight heparin (LMWH).

Main Results:

  • Low-molecular-weight heparin (LMWH) is established as a preferred agent for VTE prophylaxis and treatment in cancer patients due to its efficacy and safety profile.
  • LMWH offers advantages including improved survival, enhanced quality of life, reduced VTE rates, and a low incidence of thrombocytopenia compared to other anticoagulants.

Conclusions:

  • Prophylaxis against VTE is recommended for hospitalized cancer patients and those undergoing major surgery.
  • Low-molecular-weight heparin (LMWH) is the first-line therapy for established VTE in cancer patients and for preventing recurrent thrombosis.